IgM Antiphospholipid Antibodies in Antiphospholipid Syndrome: Prevalence, Clinical Associations, and Diagnostic Implications—A Scoping Review
Journal of Clinical Medicine · 11.10.2025 · 14 (20) · 7164
DOI: 10.3390/jcm14207164 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.10.2025. Verfasst von Monika Očková und 5 weiteren Autor:innen. Beteiligte Einrichtung: Systemic Autoimmune Diseases Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Gravida Fertilitat Avançada, Gravida/UAB Catedra Medicina i Immunologia Reproductiva.
Abstract (Originalsprache)
Background
IgM antiphospholipid antibodies (aPL) were de-emphasised in the 2023 ACR/EULAR criteria, yet their precise clinical significance remains uncertain.
Methods
A rapid scoping review of PubMed (January 2000–June 2025) identified original human studies reporting IgM aCL, aβ2GPI, or aPS/PT prevalence or outcomes; 40 studies met the eligibility criteria. Prevalence and odds ratios (ORs) of clinical associations were extracted.
Results
IgM aPL are common across APS phenotypes. Obstetric cohorts showed aCL-IgM prevalences of 3–82%, often equal to or exceeding those of IgG, while aβ2GPI-IgM reached a prevalence of 2–63%. In mixed thrombotic–obstetric cohorts, aPS/PT-IgM was the most frequent isotype (31–79%). Purely thrombotic studies still reported 0–59% aβ2GPI-IgM, with PS/PT-IgM at 55% and 62% in two large series. Significant outcome signals from clinical associations of IgM aPL were inconsistent but noteworthy in (i) pregnancy loss for high-titre aCL, aβ2GPI, and aPS/PT, (ii) thrombosis driven by aPS/PT and (iii) organ-specific arterial events (retinal thrombosis and stroke) in isolated IgM phenotypes.
Conclusions
The role of aPL-IgM remains uncertain. The findings advocate for a nuanced approach to IgM interpretation, supporting its reconsideration in specific clinical settings and emphasising the significance of ongoing research into the mechanistic and prognostic utility of IgM aPL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Systemic Autoimmune Diseases Research Unit, Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
- Department of Internal Medicine, Hospital Sant Camil, Consorci Sanitari del Garraf, 08810 Barcelona, Spain.
- Department of Internal Medicine, Hospital Universitari Vall d'Hebron (HUVH), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
- Department of Medicine, Universitat Autònoma de Barcelona (UAB), Vall d'Hebron Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
ORCID-Profile: Monika Očková, Ariadna Anunciación-Llunell, Enrique Esteve-Valverde, Francesc Miró-Mur
Förderung
- Instituto de Salud Carlos III
- Gravida Fertilitat Avançada
- Gravida/UAB Catedra Medicina i Immunologia Reproductiva
Zitieren
APA
Očková, M., Anunciación-Llunell, A., Andrada, C., Esteve-Valverde, E., Miró-Mur, F., & Alijotas-Reig, J. (2025). IgM Antiphospholipid Antibodies in Antiphospholipid Syndrome: Prevalence, Clinical Associations, and Diagnostic Implications—A Scoping Review. Journal of Clinical Medicine, 14(20), 7164. https://doi.org/10.3390/jcm14207164
Vancouver
Očková M, Anunciación-Llunell A, Andrada C, Esteve-Valverde E, Miró-Mur F, Alijotas-Reig J. IgM Antiphospholipid Antibodies in Antiphospholipid Syndrome: Prevalence, Clinical Associations, and Diagnostic Implications—A Scoping Review. Journal of Clinical Medicine. 2025;14(20):7164. doi:10.3390/jcm14207164
BibTeX
@article{Okov2025,
author = {Očková, Monika and Anunciación-Llunell, Ariadna and Andrada, Catalina and Esteve-Valverde, Enrique and Miró-Mur, Francesc and Alijotas-Reig, Jaume},
title = {IgM Antiphospholipid Antibodies in Antiphospholipid Syndrome: Prevalence, Clinical Associations, and Diagnostic Implications—A Scoping Review},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {20},
pages = {7164},
doi = {10.3390/jcm14207164}
}
EUVIMED